Menu Search
Equities

Turnstone Biologics Corp

TSBX:NMQ

Turnstone Biologics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.67
  • Today's Change-0.005 / -0.67%
  • Shares traded33.30k
  • 1 Year change-83.78%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 19:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Turnstone Biologics Corp have a median target of 6.00, with a high estimate of 10.00 and a low estimate of 3.75. The median estimate represents a 789.55% increase from the last price of 0.6745.
High1,382.6%10.00
Med789.5%6.00
Low456.0%3.75

Earnings history & estimates in USD

On Aug 14, 2024, Turnstone Biologics Corp reported 2nd quarter 2024 losses of -0.92 per share. This result was in line with the consensus of the 3 analysts following the company and exceeded last year's 2nd quarter results by 87.83%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+22.27%
Turnstone Biologics Corp reported annual 2023 losses of -4.78 per share on Mar 21, 2024.
More ▼

Revenue history & estimates in USD

Turnstone Biologics Corp did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Turnstone Biologics Corp had revenues for the full year 2023 of 19.31m. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.